Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
As of close of business last night, Cogent Biosciences Inc’s stock clocked out at $4.64, up 2.88% from its previous closing price of $4.51. In other words, the price has increased by $2.88 from its previous closing price. On the day, 1.03 million shares were traded.
Ratios:
To gain a deeper understanding of COGT’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.32 and its Current Ratio is at 5.32. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.06.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Scotiabank on March 07, 2025, initiated with a Sector Outperform rating and assigned the stock a target price of $17.
Robert W. Baird Downgraded its Outperform to Neutral on February 26, 2024, whereas the target price for the stock was revised from $14 to $8.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jan 14 ’25 when Pinnow Cole bought 43,750 shares for $7.60 per share. The transaction valued at 332,412 led to the insider holds 45,848 shares of the business.
Stock Price History:
Over the past 52 weeks, COGT has reached a high of $12.61, while it has fallen to a 52-week low of $3.72. The 50-Day Moving Average of the stock is -26.65%, while the 200-Day Moving Average is calculated to be -47.37%.
Shares Statistics:
A total of 110.46M shares are outstanding, with a floating share count of 95.39M. Insiders hold about 16.22% of the company’s shares, while institutions hold 91.52% stake in the company.
